LDN193189 is a highly potent cell permeable small molecule BMP inhibitor; inhibiting BMP type I receptors ALK2 (IC50: 5 nM), ALK3 (IC50: 30 nM) and ALK6 (TGFβ1/BMP signaling) and subsequent SMAD1, SMAD5, and SMAD8 phosphorylation (1, 2). It only has weak effect on ALK4, ALK5 and ALK7. LDN-193189 shows significant in vivo clinical utility, inhibiting FOP and ectopic ossification and a potential agent in the treatment of NSCLC lung tumors. Using LDN193189 can accelerates developmental timing and converts human pluripotent stem cells into nociceptors (3).